A detailed history of Aqr Capital Management LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 30,120 shares of RVNC stock, worth $77,408. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,120
Holding current value
$77,408
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.65 - $9.31 $140,058 - $280,417
30,120 New
30,120 $148,000
Q2 2023

Aug 14, 2023

SELL
$24.7 - $37.61 $17,709 - $26,966
-717 Reduced 5.05%
13,483 $341,000
Q1 2023

May 15, 2023

BUY
$18.36 - $35.27 $260,712 - $500,834
14,200 New
14,200 $457,000
Q4 2021

Feb 14, 2022

SELL
$12.46 - $27.87 $120,749 - $270,088
-9,691 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$26.8 - $31.84 $174,655 - $207,501
-6,517 Reduced 40.21%
9,691 $287,000
Q1 2021

May 17, 2021

SELL
$24.03 - $29.97 $33,305 - $41,538
-1,386 Reduced 7.88%
16,208 $453,000
Q4 2020

Feb 16, 2021

SELL
$23.41 - $28.34 $59,625 - $72,181
-2,547 Reduced 12.65%
17,594 $499,000
Q3 2020

Nov 16, 2020

BUY
$23.23 - $34.3 $158,846 - $234,543
6,838 Added 51.4%
20,141 $506,000
Q2 2020

Aug 17, 2020

BUY
$12.6 - $26.55 $167,617 - $353,194
13,303 New
13,303 $325,000
Q4 2018

Feb 14, 2019

SELL
$18.06 - $24.96 $146,033 - $201,826
-8,086 Closed
0 $0
Q3 2018

Nov 15, 2018

SELL
$23.55 - $30.1 $121,588 - $155,406
-5,163 Reduced 38.97%
8,086 $201,000
Q2 2018

Aug 14, 2018

BUY
$27.45 - $33.35 $1,070 - $1,300
39 Added 0.3%
13,249 $364,000
Q1 2018

May 15, 2018

BUY
$29.15 - $37.4 $10,377 - $13,314
356 Added 2.77%
13,210 $407,000
Q4 2017

Feb 14, 2018

BUY
$24.55 - $36.3 $60,466 - $89,406
2,463 Added 23.7%
12,854 $460,000
Q3 2017

Nov 14, 2017

BUY
$22.55 - $28.1 $234,317 - $291,987
10,391
10,391 $286,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.